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Introduction: Carcinoid tumors are variants of neuroendocrine tumors that typically arise from the gastrointestinal
tract and the bronchus, but they can involve any organ. Unresolved right shoulder pain manifesting as the first
clinical presentation of carcinoid tumor with unknown primary origin is a rare clinical entity. To the best of our
knowledge, herein we present the first case report describing metastasis to the right shoulder joint in a patient
who presented with bone pain as the first clinical manifestation of metastatic carcinoid tumor of unknown primary
origin. Metastasis to the right scapula as the first presentation of an underlying carcinoid tumor in the primary
bronchus has been reported previously.
Case presentation: A 72-year-old Caucasian woman presented with pain in her right shoulder after a fall. She
delayed seeking medical attention for 4 weeks for personal reasons. Her physical examination revealed no erythema
or swelling of the right shoulder. However, tenderness was noted on the right subacromial bursa and the right
acromioclavicular joint. Her drop arm test was positive. An X-ray of the right upper extremity showed no fracture.
She did not respond to methylprednisolone injections or physical therapy. Because of the unresolved right shoulder
pain with disturbance of her daily activities, magnetic resonance imaging of the right shoulder was ordered, which
revealed permeative destruction of the right scapula. Because the permeative destruction of the bone could have
been an osteolytic malignant feature, positron emission tomography–computed tomography was performed, which
produced a scan showing osseous metastasis to the right scapula, multiple liver metastases and a 1.7cm right-lower-lobe
pulmonary nodule. Her serotonin and chromogranin A levels were significantly elevated. The patient was treated with
palliative cisplatin and etoposide chemotherapy followed by locoregional treatments for metastatic carcinoid tumor.
She had mild improvement in her right shoulder pain, as well as better range of motion and improved quality of life,
before she died less than 2 years after her diagnosis.
Conclusion: Our present case report emphasizes the protean manifestations of carcinoid tumors with the importance
of early diagnosis of bone metastases from these tumors, because early diagnosis plays a major role in choosing the
therapeutic regimen and prognosticating the course of the disease. The treatment goals for high-grade, poorly
differentiated carcinoid tumors of unknown origin are decreasing the tumor load while controlling symptoms with
chemotherapy and local modality treatments.
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Carcinoid tumor is one of the variants of neuroendo-
crine tumors. The incidence of carcinoid tumors is 2 per
100,000 general population [1,2]. Carcinoid tumors are
often indolent tumors due to very slow growth, although
some are high-grade with malignant features, which lead
to high morbidity and mortality. Traditionally, carcinoid
tumors are thought to derive from three main embry-
onic divisions of the gut: foregut carcinoids from lungs,
bronchus or stomach; mid-gut carcinoids from the small
intestine, appendix or proximal large bowel; and hindgut
carcinoids from the distal colon or rectum [3]. Most car-
cinoid tumors arise from the gastrointestinal tract (65%),
followed by the bronchi (25%) [4], but they can involve
any organ.
Bone metastasis from carcinoid tumors was under-
estimated before the advancement of magnetic reson-
ance imaging (MRI), octreotide scanning and [123I]
metaiodobenzylguanidine and bone scintigraphy. In
one study, only 12% of metastatic carcinoid tumors
were found to have symptomatic bone metastases [5].
Bone pain, bone fracture and cord compression are
the few possible clinical symptoms that suggest stage
IV metastatic disease in patients with neuroendocrine
tumors [6]. The most common metastatic area is the
axial spine within the thoracic vertebrae (40%),
followed by lumbar vertebrae (34%) and cervical
vertebrae (32%) [7]. Less commonly, ribs and pelvic
metastases are found [7]. In the present report, we
describe the case of a patient with a highly aggressive
malignant carcinoid tumor with an unusual presenta-
tion and without a defined primary site.Figure 1 Magnetic resonance imaging scan of the patient’s right shou
(black arrow).Case presentation
A 72-year-old Caucasian woman presented with pain in
her right shoulder after having a fall from a ladder at
home. She had not sought medical attention for 4 weeks
for personal reasons. At her initial presentation, she had
increasing pain with limited range of motion in all direc-
tions. She had a medical history of melanoma in situ on
her mid-back, which was status post-excision 6 years
ago. She had exposure to asbestos at work of unknown
duration. She had never smoked or drunk alcohol in her
life. She had no weight loss, fever or night sweats. Her
physical examination revealed no erythema, swelling or
warmth on the right shoulder joint. However, her right
subacromial bursa and acromioclavicular joint were ten-
der. Her drop arm test was positive. She also had no ab-
normal skin lesions such as melanocytic nevi. An X-ray
of her right upper extremity showed no fracture. She
was referred to an orthopedist because of unresolved
right shoulder pain. She did not respond to methylpred-
nisolone injections. She underwent physical therapy for
her right shoulder joint, but without pain relief. She also
did not tolerate immobilization with a sling. MRI of her
right upper extremity showed a permeative, destructive
lesion of the right scapula (Figure 1).
Because of persistent pain in her right shoulder, the
patient underwent computed tomography (CT) of her
right shoulder, which showed no fracture, dislocation or
pathologic bone lesion on her right shoulder but
incidentally revealed a rounded, 2cm, right lower lobe
lung mass (Figure 2). As the solitary pulmonary nodule
was suggestive of malignancy on chest CT, positron
emission tomography-computed tomography (PET-CT)lder shows permeative destruction of the right scapula
Figure 2 Computed tomography scan of right shoulder without intravenous contrast incidentally shows a rounded 2cm right lower
lobe pulmonary mass (white arrow) with no pathologic lesion on right shoulder.
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right scapula, multiple liver metastatic nodules and a
1.7cm right-lower-lobe pulmonary nodule (Figure 3A-B).
The patient was then referred to an oncologist. She was
found to have non-tender hepatomegaly. Therefore, re-
ferred pain to the right shoulder from underlying hepato-
megaly versus bone pain from metastasis was suspected.
Tumor load was found to be high in the liver and bone
with a solitary malignant lung nodule. Widespread me-
tastases of underlying cancer with an unknown primary
site were found.
Because the liver was the most easily accessible organ
with multiple metastases in this case, the patient wasFigure 3 A Position emission tomography scan in coronal view shows
lobe lung nodule (red arrow) and multiple liver metastases (blue arro
scan in coronal view shows metastasis to right scapula (green arrow), a 1.7
metastases (blue arrow).referred for a liver biopsy. A core biopsy of the mass in
the left lobe of her liver showed a high-grade, poorly dif-
ferentiated neuroendocrine carcinoma. Histologically, the
differential diagnosis consisted of small-cell carcinoma
(Figure 4A-B). However, immunohistochemical staining
was positive for neuron-specific enolase, synaptophysin
and chromogranin A in tumor cells, confirming neuroen-
docrine cancer.
As most small-cell carcinomas may originate from the
lung, the patient was recommended to undergo CT-
guided biopsy of the right lung mass, which also showed
poorly differentiated carcinoma with mixed small-cell and
non-small-cell lung cancer features (Figure 5A-B).metastasis to right scapula (green arrow), a 1.7cm right lower
w). B Position emission tomography-computed tomography fusion
cm right lower lobe lung nodule (red arrow) and multiple liver
Figure 4 Stained histological biopsy tissue specimens from left lobe of the liver. A: Core biopsy tissue of the left lobe of the liver shows a
poorly differentiated neuroendocrine tumor suggestive of small-cell carcinoma (original magnification, 400×). B: Core biopsy tissue of the left lobe
of the liver shows a poorly differentiated neuroendocrine tumor suggestive of small-cell carcinoma (original magnification, 100×).
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granin A, synaptophysin, cytokeratin 7 and thyroid tran-
scription factor 1 and weakly positive for cytokeratin 20.
The 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA)
test result was 42mg/24h (reference range, ≤6mg/24h).
Urinary 5-HIAA has sensitivity of 73% and specificity of
100% for carcinoid tumors [8]. 5-HIAA is the metabolic
product of serotonin. The patient’s serotonin and chromo-
granin A levels are given in Table 1. Chromogranin A has
sensitivity of 62.9% and specificity of 98.4% for carcinoid
tumors [9-11]. Serotonin is broken down by the liver and
excreted in urine as 5-HIAA. A metastatic, poorly differ-
entiated, stage IV carcinoid tumor was diagnosed on the
basis of liver and bone metastases and a right lower lobe
lung nodule with no defined primary site. In order to
identify the primary site of the carcinoid tumor, whole-
body octreoscan imaging with planar single-photon emis-
sion computed tomography was performed, which showedFigure 5 Stained histological biopsy tissue specimens from right lower
pulmonary nodule shows non-small-cell lung cancer features (original magnif
nodule also shows small-cell carcinoma features (original magnification, 400×no evidence of octreotide-avid malignancy. The liver le-
sions visualized on the recent PET-CT scan were “cold”
on the octreotide scan.
The goals of treating high-grade, poorly differentiated
carcinoid tumors of unknown origin are decreasing the
tumor load and palliation of symptoms. Our patient was
offered chemotherapy with cisplatin and etoposide. At her
follow-up examination after two cycles of chemotherapy,
the patient had some improvement in pain and better
range of motion of the right shoulder. A repeat PET
scan taken after two cycles of chemotherapy showed a
mixed response to chemotherapy. The standardized up-
take value (SUV) of the right scapular lesion had dimin-
ished from 6.4 to 5.4. The SUV of the right side of the
vertebral body at T8 had decreased from 4.8 to 4.4.
Diffuse, generalized hepatic metastases had increased in
size, and there was one new 1.5cm hypermetabolic
right-lower-lobe pulmonary nodule. The patient-lobe pulmonary nodule. A: Core biopsy tissue of the right lower-lobe
ication, 400×). B: Core biopsy tissue of the right lower-lobe pulmonary
).














Serotonin 1,322 554 278 – 825 22 to 180
Chromogranin A 148 210 152 150 98 1.9 to 15
HAE, Hepatic artery embolization.
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etoposide. A CT scan of the abdomen after chemother-
apy showed bulky, centrally necrotic liver metastases
with nearly total involvement of the left hepatic lobe
and pulmonary metastases within the right lung abutting
the mediastinal pleura, indicating an inadequate response
to treatment. The patient still had high serotonin and
chromogranin A levels (Table 1). Therefore, hepatic artery
embolization (HAE) of the right hepatic artery was per-
formed, along with administration of octreotide to miti-
gate tumor burden from liver metastases. The patient’s
disease activity decreased, as indicated by the biochem-
ical markers listed in Table 1, although her chromogranin
A level was still elevated.
One month later, the patient also received embolization
of the left hepatic artery with a second dose of octreotide.
Her hepatomegaly decreased. Symptomatically, she felt
better. Her liver disease responded favorably to embolization.
Post-embolization syndrome with nausea and low-grade
fever resolved with symptomatic treatment with anti-
nausea medication, hydration and a short-term hospital
stay after she underwent a second HAE. At a follow-up
examination after her second HAE, the patient com-
plained of pain in her right shoulder, which was graded 5
of 10 in severity with weakness and reduced range of mo-
tion. Cryoablation of the right shoulder was offered to the
patient. A CT scan of her right upper extremity showed
asymmetric atrophy involving the musculature of the right
rotator cuff, including the subscapularis, supraspinatus
and infraspinatus muscles as well as the right deltoid
muscle. Increased lytic destruction involving the inferior
part of the right glenoid was observed, with a tumor ex-
tending through the posterior cortex at the spinoglenoid
notch. The patient underwent cryoablation of the right
shoulder, which resulted in partial relief of the pain. Three
months after embolization of the left hepatic artery, CT
scans of the abdomen with and without contrast were re-
peated, which showed metastases in the medial left hep-
atic lobe and the posterior right hepatic lobe. The patient
underwent embolization of right hepatic artery, including
the cystic artery. Tumor activity in this case was resistant
to treatment, requiring multiple episodes of local modality
treatments with HAE. The patient also developed a
soft-tissue mass on the left posterior chest wall about
2cm×2cm in size. An excisional biopsy of the mass
showed a metastatic, poorly differentiated neuroendocrinetumor. Unfortunately, despite systemic chemotherapy, re-
peated HAE and cryoablation of the right shoulder, the
pain in the patient’s right shoulder remained to a certain
extent. She had no systemic symptoms of carcinoid syn-
drome, such as diarrhea, flushing, cardiac arrhythmia and
shortness of breath, throughout the disease course. She
eventually died as a result of liver failure.Discussion
Carcinoid tumors are neuroendocrine tumors derived
from enterochromaffin cells, also called Kulchitsky cells.
Neuroendocrine cells are distributed throughout the
whole body, have a similar histological appearance upon
diagnosis and can release many neurosecretory granules,
such as serotonin, gastrin, somatostatin and substance P.
The capacity to secrete a variety of neuropeptides from
enterochromaffin cells triggers the symptoms. Depend-
ing on the location of the primary carcinoid tumor with
or without metastases, symptoms of carcinoid tumors
can vary. Although a majority of carcinoid tumors have
indolent disease activity, they can have an aggressive dis-
ease course different from classic carcinoid syndrome, as
we observed in our patient. The 5-year overall survival
rate for carcinoid tumor patients, regardless of site, is
67% [12]. If there are distant metastases to bone, liver
and other organs, the 5-year survival rate ranges from
4% to 35% [13]. Our present case report describes a pa-
tient who was incidentally diagnosed with malignant
carcinoid tumor with high-grade features and lung,
bone and liver metastases of unknown origin.
Poorly differentiated neuroendocrine cancer is aggres-
sive in nature and it can present with multiple metasta-
ses, including liver, bone, lung and brain, at the onset of
presentation. It is usually locally aggressive and becomes
unresectable. In such cases, investigation for the primary
site of cancer origin may involve extensive imaging with
contrast-enhanced CT or MRI scans, octreotide scans,
capsule endoscopy, endoscopic ultrasound and even lap-
aroscopic surgery. However, the decision to order several
diagnostic tests for the detection of the primary site
should be tailored specifically for each patient. Our pa-
tient had a negative octreotide scan, and we were unable
to detect the primary site by using this specialized im-
aging technique. A negative octreotide scan implies that
tumor cells may not have somatostatin receptors. In our
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burden and did not respond adequately to octreotide.
At the time of her presentation, our patient did not
have any symptoms other than right shoulder pain pre-
cipitated by a fall. She was found to have numerous liver
metastases with poorly differentiated neuroendocrine
features, indicating a poor prognosis, thus she was rec-
ommended to undergo systemic chemotherapy with cis-
platin and etoposide. Even though treatment with
systemic chemotherapy is neither curative nor effective,
Fjällskog et al. reported that treatment with cisplatin
and etoposide led to radiological and/or biochemical re-
sponses in 56% of 18 patients with foregut carcinoids
and 50% of 14 patients with malignant endocrine pan-
creatic tumors, with a median response duration of 9
months [14]. Mitry et al. confirmed that poorly differen-
tiated neuroendocrine tumors respond to the cytotoxic
agents cisplatin and etoposide, although the 2-year sur-
vival is less than 20% [15]. Therefore, patients can be ef-
fectively palliated by cisplatin and etoposide treatment
without significant morbidity. As shown in our present
case, an interventional radiology–guided procedure par-
tially relieved the patient’s symptoms of pain in the right
shoulder. Until more effective chemotherapy is devel-
oped, palliation with chemotherapy is the goal.
Our patient had some improvement in her right shoul-
der pain and better range of motion after two cycles of
chemotherapy. During chemotherapy, she experienced
side effects of diarrhea and poor appetite. She also
underwent repeated HAE for numerous liver metastases,
which persisted despite receiving systemic chemother-
apy. Our patient had no symptoms of carcinoid syn-
drome, despite the involvement of large liver metastases.
Metastatic carcinoid tumors can have either osteo-
blastic or osteolytic lesions, with the latter thought to
carry a worse prognosis [7]. Our patient had permeative
destruction of the right scapula at her initial presenta-
tion, which could have been one of the adverse prognos-
tic factors. This illustrates the need for repeated HAE to
reduce tumor burden in our patient. Our patient also
developed skin metastasis to a left chest wall lesion. The
manifestation of skin metastases from carcinoid tumors
has been reported in the past and is usually a sign of
advanced disease.
Conclusion
Carcinoid tumors can arise from any epithelial cell
throughout the whole body and they can exhibit neu-
roendocrine behavior, although they are typically rec-
ognized on the basis of gastrointestinal complaints.
The case of our patient demonstrates a rare initial clin-
ical presentation of metastatic carcinoid tumor with
right shoulder pain after the patient had a fall. The
diagnosis was challenging. The patient was treatedwith palliative chemotherapy, locoregional treatment
with HAE and cryoablation of the shoulder. She had
partial relief of her right shoulder pain and relief of
cachexia, as well as improved quality of life with the
above treatments, before she died less than 2 years
after her diagnosis.
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